SanBio Co Ltd (SNBIF) Ganando

SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 29 full-time employees. The company went IPO on 2015-04-08. The firm has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The firm aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. The company is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The firm has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).